Company intelligence / Profile preview
Coya Therapeutics, Inc.
Houston, Texas, United Statescoyatherapeutics.com ↗
- Ownership
- Public · COYA
- Employees
- ~8
- Development stage
- Phase 1
01
Overview
Coya Therapeutics has completed a controlled Phase 2 study of Low Dose Interleukin-2 in Alzheimer's Disease patients and reported positive interim results from an investigator-initiated open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with mild to moderate Frontotemporal Dementia. The company is preparing to initiate a randomized, double-blind controlled Phase 2b trial in ALS patients upon IND acceptance.
- Therapeutic areas
- ImmunologyNeurologyMetabolic Disorders
- Modalities
- Treg-enhancing biologicsTreg-derived exosomesAutologous Treg cell therapyLow-dose IL-2 (LD IL-2)CTLA4-Ig combination
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Houston Methodist Research InstituteJohnson Center for Cellular TherapeuticsAlzheimer's Drug Discovery Foundation (ADDF)
04
Financials
- Market cap
- $108.1M
- Total revenue
- $243.7K
- Enterprise value
- $-43.1B
Beyond the preview
Go deeper on Coya Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coya Therapeutics, Inc..